Salute e Benessere

First Characterization of a TDP-43 PET Tracer Published in Nature Communications…

First Characterization of a TDP-43 PET Tracer Published inNature CommunicationsShowing Potential of AC Immune’s ACI-19626 in Precision Medicine Aggregated TDP-43 is a pathological hallmark of neurodegenerative diseases including ALS, FTD and LATE, and a co-pathology in Alzheimer’s and Parkinson’s diseasesPET imaging of aggregated TDP-43 could facilitate precision medicine in these diseases, whose shared clinical features complicate differential diagnosis, potentially delaying...

Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology…

The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many inflammatory diseasesCAMBRIDGE, Mass. and CHICAGO, Oct.24, 2025(GLOBE NEWSWIRE) -- BiogenInc. (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua’s preclinical, oral C5aR1 antagonist. This agreement strengthens Biogen’s immunology strategy by advancing a proven immune mechanism with the potential to...

Sobi showcases new data across rare inflammatory conditions at ACR 2025

Summary of full Sobi data to be presented at ACR 2025: Summary of full Sobi data to be presented at ACR 2025: Date: Tuesday 28 October Session time: 1:00 PM - 2:30 PM CT Presentation time: 1:30 PM - 1:45 PM CT Date: Tuesday 28 October Session time: 1:00 PM - 2:30 PM CT Presentation time: 1:45 PM - 2:00 PM CT Date: Monday 27 October Presentation time: 10:30 AM - 12:30 PM CT Date: Tuesday 28 October Presentation time: 10:30 AM - 12:30 PM CT ...

The Future of Life Sciences, Omics and AI Examined by Leading Global Genomic…

Discussions will span global collaboration in omics and AI, cancer genomics, biodiversity and multi-omics of deep-sea organisms, metagenomics and epidemiology, public health and precision medicine, and the transformative potential of AI in healthcare and across life sciences. Discussions will span global collaboration in omics and AI, cancer genomics, biodiversity and multi-omics of deep-sea organisms, metagenomics and epidemiology, public health and precision medicine, and the transformative...

Ribo Granted EMA Orphan Drug Designation for siRNA Therapeutic RBD1016 for…

About Hepatitis D Virus (HDV)HDV is the most severe form of viral hepatitis and occurs only in individuals co-infected with hepatitis B virus (HBV). HDV accelerates liver disease progression, significantly increasing the risk of cirrhosis, liver failure, and hepatocellular carcinoma. It is estimated that 12–20 million people globally are affected by HDV, with limited therapeutic options currently available. About Hepatitis D Virus (HDV)HDV is the most severe form of viral hepatitis and...

Smartee Strengthens European Presence with New UK Subsidiary and Orthodontic…

Leveraging 21 years of expertise in clear aligner technology, the Smartee UK team will collaborate with local dental institutions, hospitals, and academic organizations to advance research, clinical training, and innovation. The center also aims to develop region-specific orthodontic solutions and organize professional education programs to support practitioners throughout Europe. Leveraging 21 years of expertise in clear aligner technology, the Smartee UK team will collaborate with local...

Vistin Pharma ASA: Invitation to Q3 2025 conference call

Vistin Pharma ASA (VISTN) will release its third quarter and YTD 2025 results on Friday 31st of October 2025. Vistin Pharma will host a conference call for all shareholders and interested parties on the same day at 08:30 CET. There will be a Q&A session following the management discussion.The conference call will be held in English.The third quarter conference call will be available via web and audio through the following access points: Webcast:https://edge.media-server...

Polpharma Group Announces Leadership Transition – Sebastian Szymanek appointed…

Polpharma Group, one of the largest pharmaceutical groups operating across Central and Eastern Europe and Central Asia, announces a planned leadership transition. EffectiveJanuary 1, 2026,Markus Sieger will step down as CEO of the Group, after a decade of dedicated service. He will continue to support the strategic development of the Group as a member of theSupervisory Board, in line with the succession plan agreed upon at the start of his tenure.Under Markus Sieger’s...

Avextra Supports Phase II Clinical Trial in Italy on Cannabis-based medicines…

First patient enrolled in randomized, placebo-controlled studyBensheim, 24. October 2025– Neurodegenerative diseases represent one of the biggest challenges of our time. In Germany alone, there are currently around 1.8 million people living with dementia, a figure that is set to rise to 2.7 million by 2050. Increased life expectancy, combined with the growing number of patients, is having an increasingly significant impact on those affected, their families, and national healthcare...

49,164 Orion Corporation A shares converted into B shares

ORION CORPORATIONSTOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE24 OCTOBER 2025 at 9.00 EEST 49,164 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 49,164 A shares have been converted into 49,164 B shares. The conversion has been entered into the Trade Register on 24 October 2025.The total number of shares in Orion Corporation is 141,134,278...

NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following…

PARIS and CAMBRIDGE, Mass., Oct.24, 2025(GLOBE NEWSWIRE) --NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updates to the JNJ-1900 (NBTXR3) clinical development program.Nanobiotix has completed the transfer of NANORAY-312 sponsorship, initiated in 3Q2024, in the majority of regions along...

ONWARD Medical Successfully Raises Over EUR 50 Million in Capital Increase

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)Successful transaction supported by strong demand from existing...

Press release: Q3: continued sales and earnings progress

Q3: continued sales and earnings progressParis, October 24, 2025Q3 sales growth of 7.0% at CER 1and business earnings per share (EPS) 2of €2.91Pharma launches increased sales by 57.1%, reaching €1.0 billion, driven by ALTUVIIIO and AyvakitDupixent sales increased by 26.2% to €4.2 billion, first time above €4 billion in a quarterVaccines sales decreased by 7.8% to €3.4 billion, from lower influenza salesResearch and Development expenses were €1.8 billion, an...

Purpose Brands Announces Grand Opening of First Anytime Fitness Club in Dubai…

"We are thrilled to bring the Anytime Fitness brand to UAE and officially open the first club's doors in Dubai," said Faheem Essop, CEO, Purple Fitness. "Every detail, including the full suite of world-class Technogym fitness equipment and the SmartCoaching ecosystem via the AF App, has been built to meet the global standards set by this world-class fitness brand. We are here to deliver accessible, personalized coaching, nutrition and recovery services for the people of…

Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast…

Mismatch Repair Deficiency Market Summary Mismatch Repair Deficiency Market Summary Discover the mismatch repair deficiency new treatment @New Treatments for Mismatch Repair Deficiency Key Factors Driving the Growth of the Mismatch Repair Deficiency Market Rising Prevalence of dMMR-Associated Cancers Mismatch repair deficiency is a hallmark of various cancers, including colorectal, endometrial, and gastric cancers. The increasing incidence of these cancers has...

Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting…

Mechelen, Belgium; October 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present newin vitropharmacological data from its selective TYK2 inhibitor, GLPG3667, currently in two Phase 3-enabling studies in dermatomyositis (DM) and systemic lupus erythematosus (SLE), at the American College of Rheumatology (ACR) Convergence 2025, taking place in Chicago, IL, October 24-29, 2025. The data show that thein vitropharmacological profile of...

Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an…

Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancer64% overall response rate in gynecological cancers at doses≥ 6.4mg/kgResponses observed at all doses evaluated at 3.2mg/kg and above demonstrating wide therapeutic index of Zymeworks’ novel antibody-drug conjugate platformDose optimization of ZW191 in ovarian cancer to initiate...

Oxurion Receives Transparency Notification from Atlas Special Opportunities II…

Leuven, BELGIUM – October 23, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows: Oxurion received a transparency notification on October 22, 2025, from Atlas Special Opportunities II…

World Psoriasis Day 2025: IFPA Calls to Stop the Domino Effect of Psoriasis

IFPA's "Stop the Domino Effect" is urging policymakers, healthcare professionals and the public to recognize psoriasis for what it is: a serious, systemic, and life-changing disease that sets off a chain reaction of serious health conditions — from diabetes and cardiovascular disease to depression. The campaign highlights the urgent need for integrated care, early intervention and equal access to treatment worldwide. The organization calls on health authorities to include psoriasis in…

Czech Breakthrough in Medicine: H₂ Global Group Receives Regulatory Approval for…

From Japanese discovery to Czech clinical practice From Japanese discovery to Czech clinical practice The project is based on pioneering research by ProfessorShigeo Ohta, co-founder of H₂ Global Group and widely regarded as thefounding father of therapeutic hydrogen medicine. Professor Ohta personally transferred his European patent (EP 3701956 B1), titled"Prophylactic or Therapeutic Agent for Dementia,"to the Group. "Launching a clinical study that directly builds on...

With Med4Cure, EUROAPI accelerates pharmaceutical innovation at the service of…

Press Release The project launch event, held at the Vertolaye site, brought together State officials, elected representatives, and several project partners to accelerate pharmaceutical innovation in EuropeParis – October 23, 2025– EUROAPI officially launched its innovation programs today as part of the Health IPCEI (Important Project of Common European Interest), a European initiative aimed at strengthening pharmaceutical sovereignty. This project, called “Med4Cure,”...

Guerbet : Revenue at September 30, 2025. Return to growth in Q3 2025…

Revenue at September 30, 2025Return to growth in Q3 20259-month revenue: €586.5 million, down 2.8% at CER 1and on a like-for-like basis 2, largely due to the fall in activity in FranceAn increase in Q3 of 2.6% at CER and on a like-for-like basis, underpinned by the acceleration of Elucirem TMsales and good momentum on Lipiodol ® Confirmation of all financial targets for 2025Villepinte, October 23, 2025, 5.45 p.m.:Guerbet (FR0000032526 GBT), a global specialist in...

Medical Device Market Surges to USD 750 Billion by 2033, Propelled by 5.5% CAGR…

Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=482507 Download PDF Brochure:https://www.verifiedmarketreports.com/download-sample/?rid=482507 Browse in-depth TOCon Medical Device Market202 – Pages 126 – Tables 37 – Figures Scope of The Medical Device Market Report Global Medical Device Market Overview Medical Device Market: Trends and Opportunities The global Medical Device Market is experiencing dynamic...

Avaz Joins the PRC-Saltillo Community, Expanding Global AAC Access and…

Narayanan Ramakrishnan, CEO of Avaz, added, "Together, we're uniquely positioned to expand access to AAC and share knowledge across borders. For both our customers and our internal teams, this means new opportunities to learn, innovate, and grow together." Narayanan Ramakrishnan, CEO of Avaz, added, "Together, we're uniquely positioned to expand access to AAC and share knowledge across borders. For both our customers and our internal teams, this means new opportunities to learn…

Altri Comunicati